Mostrando 10 resultados de: 13
Publisher
Cancer Biology and Therapy(3)
Annals of Oncology(1)
Cancers(1)
Clinical Cancer Research(1)
Frontiers in Pharmacology(1)
Área temáticas
Enfermedades(13)
Farmacología y terapéutica(8)
Medicina y salud(3)
Bioquímica(1)
Fisiología humana(1)
Origen
scopus(13)
Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile
ArticleAbstract: Nimotuzumab is an EGFR-targeting antibody that has demonstrated encouraging clinical results in thePalabras claves:Affinity, Avidity, Cancer immunotherapy, eGFR, monoclonal antibodies, nimotuzumab, Tumor targetingAutores:Fernandez L.E., Garrido G., Gracia E., Iznaga N., Kerbel R.S., Pérez R., Rabasa A., Tania Crombet, Tikhomirov I.A., Yang E.Fuentes:scopusAntiproliferative, antiangiogenic and proapoptotic activity of H-R3: A humanized anti-EGFR antibody
ArticleAbstract: The epidermal growth factor receptor (EGFR) proto-oncogene is frequently overexpressed in tumors ofPalabras claves:Angiogenesis, Epidermal growth factor receptor (EGFR), H-R3, Monoclonal antibody, Signal inhibitorsAutores:Pérez R., Rak J., Tania Crombet, Viloria-Petit A.Fuentes:scopus1E10 anti-idiotype vaccine in non-small cell lung cancer: Experience in stage IIIb/IV patients
ArticleAbstract: Conventional treatment of non-small cell lung cancer (NSCLC) has apparently reached a plateau of effPalabras claves:Anti-idiotype antibody, Cancer Vaccines, Clinical study, immunotherapyAutores:Aguirre F., Alfonso S., Alonso D.F., Barroso M.C., Carmen Elena Viada, De La Torre A.V., Díaz R.M., Gabri M.R., Gómez R., Hernández A.M., Macías A.E., Pérez K., Pérez R., Rodríguez J., Santiesteban E.R., Suárez E., Toledo D., Vázquez A.M.Fuentes:scopusA randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients
ArticleAbstract: Purpose: Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-associated gangliPalabras claves:Autores:Alfonso S., Areces F., Carmen Elena Viada, Cepeda M., Chong E., De La Torre A.V., Flores Y.I., García E., Gonzalez Z., Guerra P.P., Hernández A.M., Hernández M., Macías A.E., Mazorra Z., Mendoza I.C., Ortiz R.A., Pérez K., Pérez R., Santiesteban E.R., Tania Crombet, Toledo D., Valdes-Zayas A., Vázquez A.M.Fuentes:scopusA view on EGFR-targeted therapies from the oncogene-addiction perspective
ArticleAbstract: Tumor cell growth and survival can often be impaired by inactivating a single oncogen - a phenomenonPalabras claves:CETUXIMAB, Combination therapy, eGFR, Erlotinib, nimotuzumab, Oncogene addiction, Targeted therapyAutores:de Leon J., Moreno E., Pérez R., Tania CrombetFuentes:scopusActive immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: Report of a phase I trial
ArticleAbstract: 1E10 is an anti-idiotype murine monoclonal antibody (Ab2 MAb) specific to an Ab1 MAb which reacts wiPalabras claves:Anti-idiotype antibody, Cancer Vaccines, Clinical study, immunotherapyAutores:Alfonso A.M., Alonso D.F., Bárbara Wilkinson, Combet T., De La Torre A.V., Díaz A., Díaz R.M., Gabri M.R., Neninger Vinageras E., Pérez R., Rives R., Saurez G., Vázquez A.M.Fuentes:scopusGangliosides, Ab1 and Ab2 antibodies. I. Towards a molecular dissection of an idiotype-anti-idiotype system
ArticleAbstract: This report is focused on the molecular basis for the interaction of a monoclonal antibody (mAb) andPalabras claves:Anti-idiotypic antibodies, H-CDR, N-Glycolyl-gangliosidesAutores:González M., López-Requena A., Mateo de Acosta C., Moreno E., Pérez R., Puchades Y., Santiago Nelson Vispo, Talavera A., Vázquez A.M.Fuentes:scopusEpidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy
ArticleAbstract: Background: The role that growth factors and their receptors play in human cancer growth and progresPalabras claves:cancer vaccine, Epidermal growth factor, Non-small-cell lung cancerAutores:Alfonso L., Catala M., García Verdecia B., González G., Lage R., Mulet A., Neninger Vinageras E., Osorio M., Pérez R., Tania Crombet, Torres F.Fuentes:scopusEGFR-targeting as a biological therapy: Understanding Nimotuzumab's clinical effects
ReviewAbstract: Current clinical trials of epidermal growth factor receptor (EGFR)-targeted therapies are mostly guiPalabras claves:biological therapy, Cancer treatment, eGFR, nimotuzumab, Targeted therapyAutores:Garrido G., Moreno E., Pérez R., Tania CrombetFuentes:scopusImmunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients
ArticleAbstract: Increased levels of NeuGc-containing gangliosides have been described in human breast cancer. A contPalabras claves:Breast Cancer, cancer vaccine, Clinical trial, Ganglioside, immunotherapy, NeuGcGM3, patientsAutores:Cardoso J., Carmen Elena Viada, Carr A., De La Torre A.V., Díaz R., Fernandez L.E., Macías A.E., Marinello P., Mazorra Z., Mulens V., O'Farrill M., Pérez R., Rodríguez R., Saurez G., Tania CrombetFuentes:scopus